Trial Information

Summary: Evaluation of the Efficacy of the NK1 Antagonist GR205171 in PTSD

In an effort to develop novel and improved treatments for Post-Traumatic Stress Disorder (PTSD), we are conducting a clinical research study to look at the effectiveness and safety of a new medication. This study is examining if the investigational medication helps to lessen PTSD symptoms, as it is believed to counteract a brain chemical called substance P, which is thought to be overactive in anxiety and stress conditions. After completing the screening process, participants will be randomly assigned to take either the investigational drug or a placebo, a pill with no active substance, for a 10-week period. Neither you nor the research team will know which of the two pills you are taking. If you are between the ages of 18 and 65 and are suffering from PTSD symptoms, you may be eligible for this study.
Compensation Provided

Patient Inclusion/Exclusion Criteria:

* Diagnosed with PTSD (as determined by the initial evaluation) that has lasted for at least 3 months prior to study entry
* A negative urine toxicology during screening
* Females willing to use an effective form of birth control throughout the study

* Current diagnosis of schizophrenia, a psychotic disorder, bipolar disorder, or other psychiatric disorder except for depression secondary to the PTSD
* History of serious medical or neurological illness (including traumatic brain injury)
* Serious suicidal or homicidal risk
* Substance and alcohol abuse or dependence within 90 days of study entry
* Current treatment with any psychoactive medication, such as antidepressants, antipsychotics, and mood stabilizers.
* Pregnant or breastfeeding

If you would like to learn more about participating in this study, please send an e-mail message using the form below.